---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-083645"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:36:35.038360+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q3 revenue $16.3M (+8% YoY); raises 2023 guidance, introduces 2024 outlook

## Summary
- GAAP net loss per share $(0.17); non-GAAP EPS $0.09 vs $0.07 YoY.
- 2023 revenue guidance raised to $68-70M; adjusted EBITDA $3-4M.
- Preliminary 2024 revenue guidance of at least $110M; adjusted EBITDA margin at least 10%.
- Completed acquisition of Medicx Health post-Q3; total DAAP deals now at 16 for 2023.
- Cash and investments $63.5M as of Sep 30, 2023.

## SEC filing metadata
- accession: 0001213900-23-083645
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/ea187745-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-083645
- JSON: https://secwatch.observer/filing/0001213900-23-083645.json
- Plain text: https://secwatch.observer/filing/0001213900-23-083645.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported full year 2023 results: revenue $68 million to $70 million. Guidance raised.
  - Period: full year 2023
  - Revenue: $68 million to $70 million
  - Guidance: raised
  - Result: guidance update
  source text: we’re increasing our guidance for 2023 and are now looking for revenue and adjusted EBITDA to come in between $68-$70 million and $3-$4 million, respectively, for the year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm
- Earnings Releases
  OptimizeRx Corp reported third quarter ended September 30, 2023 results: net income $(2.9) million, EPS $(0.17).
  - Period: third quarter ended September 30, 2023
  - Net income: $(2.9) million
  - EPS: $(0.17)
  - Result: reported results
  source text: ● Revenue in the third quarter of 2023 increased 8% to $16.3 million, as compared to $15.1 million in the same year ago period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm
- Earnings Releases
  OptimizeRx Corp reported third quarter ended September 30, 2023 results: net income $(2.9) million, EPS $(0.17).
  - Period: third quarter ended September 30, 2023
  - Net income: $(2.9) million
  - EPS: $(0.17)
  - Result: reported results
  source text: ● GAAP net loss totaled $(2.9) million or $(0.17) per basic and diluted shares outstanding in the third quarter, as compared to $(3.5) million or $(0.19) during the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm
- Earnings Releases
  OptimizeRx Corp reported 2024 results: revenue at least $110 million. Guidance initiated.
  - Period: 2024
  - Revenue: at least $110 million
  - Guidance: initiated
  - Result: guidance update
  source text: We’re also introducing preliminary 2024 guidance and expect revenue to be at least $110 million and expect adjusted EBITDA margins to be at least 10%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.